ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.
The financing was led by a new investor and supported by current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision.
The ViaLase laser is designed to help ophthalmologists precisely create channels in the trabecular meshwork through a “noninvasive, nonsurgical approach,” using femtosecond laser image-guided high-precision trabeculotomy,